Compare iShares US Aerospace & Defense ETF (ITA) vs Tango Therapeutics Inc. (TNGX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
iShares US Aerospace & Defense ETF vs Tango Therapeutics Inc. — how do they compare? iShares US Aerospace & Defense ETF trades at $204.16 (market cap $11.96B), while Tango Therapeutics Inc. trades at $22.23 (market cap $3.75B). The key difference: iShares US Aerospace & Defense ETF is far larger — about 3.2× Tango Therapeutics Inc.'s market cap, and Tango Therapeutics Inc. is trading nearer its 52-week high, iShares US Aerospace & Defense ETF nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold iShares US Aerospace & Defense ETF for 24 Days and Tango Therapeutics Inc. for 0 Days on average.
| ITA | TNGX | |
|---|---|---|
Market Cap | $11.96B | $3.75B |
Volume | 750,577 | 9,619,106 |
Sector | Sector/Thematic | Health |
52-Week High | $253.22 | $32.90 |
52-Week Low | $198.23 | $7.50 |
Typical Hold Time | 24 Days | 0 Days |
Enterprise Value | — | $2.77B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ITA trades at $204.00, down 0.99% with bearish technical signals from moving averages. The ETF shows neutral oscillators but faces selling pressure with RSI at oversold levels. Recent corporate actions include a 1:3 stock split scheduled for November 2026 and a $0.25 dividend payment in September 2026. Defense sector momentum remains strong with multiple contract wins and geopolitical tensions driving demand.
The defense sector outlook appears favorable with increased government spending and geopolitical tensions, though ITA faces technical headwinds. Key risks include defense budget volatility and geopolitical resolution. Analyst sentiment remains mixed with the ETF positioned to benefit from ongoing military modernization programs and replenishment of defense inventories.
TNGX trades at $22.22, down 8.07% in the last session, reflecting negative investor reaction to recent earnings misses. The stock shows neutral technical signals with key support at $21 and resistance at $23. Fundamentally, the company maintains a high gross margin of 98.25% but faces significant losses with a net income margin of -229.92% and negative cash flow from operations. Recent news highlights institutional buying interest and upcoming clinical trial developments.
Despite strong analyst support with a $45.91 consensus price target (107% upside), TNGX faces substantial execution risks as a clinical-stage biotech. The company's heavy cash burn and lack of profitability require careful monitoring of pipeline progress. Investment appeal hinges on successful drug development outcomes rather than current financial metrics.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About iShares US Aerospace & Defense ETF
iShares U.S. Aerospace & Defense ETF seeks to track U.S. companies in the aerospace and defense sector. Its holdings include manufacturers of commercial and military aircraft, defense systems, and related equipment.
Read more on ITA →About Tango Therapeutics Inc.
Tango Therapeutics, Inc. is a clinical-stage biotechnology company focused on precision oncology, developing cancer therapies based on the genetic principle of synthetic lethality, including its PRMT5 inhibitor program.
Read more on TNGX →
